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Urinary excretion of N-benzoyl-glycyl-Nε-(hexanonyl)lysine, a biomarker of oxidative stress, was higher in 26 patients with
active systemic lupus erythematosus (SLE) than in 11 non-SLE patients with connective tissue diseases and in 14 healthy
volunteers. We hypothesized that increased oxidative stress in active SLE might be attributable to deranged bioenergetics, defective
reduction-oxidation (redox) capacity, or other factors. We demonstrated that, compared to normal cells, T lymphocytes (T) and
polymorphonuclear neutrophils (PMN) of active SLE showed defective expression of facilitative glucose transporters GLUT-3 and
GLUT-6,whichledtoincreasedintracellularbasallactateanddecreasedATPproduction.Inaddition,theredoxcapacity,including
intracellular GSH levels and the enzyme activity of glutathione peroxidase (GSH-Px) and γ-glutamyl-transpeptidase (GGT), was
decreased in SLE-T. Compared to normal cells, SLE-PMN showed decreased intracellular GSH levels, and GGT enzyme activity
was found in SLE-PMN and enhanced expression of CD53, a coprecipitating molecule for GGT. We conclude that deranged
cellular bioenergetics and defective redox capacity in T and PMN are responsible for cellular immune dysfunction and are related
to increased oxidative stress in active SLE patients.
1.Introduction
Systemic lupus erythematosus (SLE) is an archetype of
systemic autoimmune disease that is characterized by diverse
immune dysfunctions. SLE patients experience increased
oxidative stress that is related to mitochondrial hyperpolar-
ization and ATP depletion [1–4]. However, the molecular
basis of this increased oxidative stress and its relationship
to immune dysfunction in SLE patients remain unclear.
A c t i v ei m m u n ec e l l ss u c ha sl y m p h o c y t e sa n dp o l y m o r -
phonuclear neutrophils (PMN) need constant energy for
both basic housekeeping and speciﬁc immune functions
such as tissue immigration, antigen processing/presentation,
signal transduction, and other eﬀector functions [5, 6]. The
oxidation of glucose provides a major source of metabolic
energy in mammalian cells. Glucose-6-phosphatase is an
enzyme that is only present in mammalian liver and kidneys
and plays an important role in producing glucose during
periods of starvation [7]. Because the lipid bilayer on the
mammalian cell surface is impermeable to the hydrophilic
and polar glucose molecules, cellular uptake of glucose is
only achieved through glucose carriers embedded in the
bilayer. The glucose transporters include sodium-dependent
cotransporters and facilitative glucose transporters (GLUT)2 Clinical and Developmental Immunology
that facilitate glucose diﬀusion along a concentration gra-
dient [8]. Each of the 14 isoforms of facilitative glucose
transporters (GLUT-1 to GLUT-13 and HMIT-1), exhibits
ad i ﬀerent aﬃnity for glucose and other hexoses. GLUT-1
and GLUT-3 possess a high aﬃnity for glucose [9]. GLUT-
1 is present at variable concentrations in many tissues
and is believed to be responsible for basal glucose uptake
[10]. GLUT-3 is mainly expressed in brain and circulating
mononuclear cells [11]. GLUT-6 is only expressed in the
spleen, leukocytes, and brain [12, 13]. There have been
few studies on the relationship between glucose transporter
expressionandthebioenergeticsofSLEimmune-relatedcells
reported in the literature.
Viora et al. [14] demonstrated that the intracellu-
lar reduction-oxidation (redox) state might aﬀect lym-
phocyte proliferation and NK-mediated cytotoxicity. The
glutaredoxin-glutathione system is the key player in redox
regulation of the cells and is composed of NADPH, reduced-
form glutathione (GSH), the ﬂavoprotein glutathione perox-
idase (GSH-Px), and glutathione reductase (GSSG-Rx) [15].
Because glutathione is present in all animal cells in high
concentrations, it acts as the most important intracellular
modulator for redox, cell proliferation, DNA synthesis,
immune responses, and arachidonic acid metabolism [16,
17]. The antioxidant glutathione must be recaptured by
γ-glutamyl-transpeptidase (GGT) [18]. Because CD53, a
glycoprotein of the tetraspanin superfamily, can coprecip-
itate with GGT activity, elevated CD53 expression in an
enhanced oxidative stress environment may prevent cell
apoptosis due to oxidative damage [19]. In the present
study, we hypothesized that deranged bioenergetics and
defective redox capacity, especially in the immune-active
cells, may be involved in the molecular basis of cel-
lular immune dysfunction and increased oxidative stress
in patients with active SLE. Our results support this
hypothesis.
2. Patientsand Methods
2.1. Patients and Controls. Fifty-four patients meeting the
2000 ACR revised classiﬁcation criteria for SLE were enrolled
in the study. An additional 52 age- and sex-matched
healthy individuals comprised the normal control group.
A second control group comprised of patients with non-
SLE connective tissue diseases was created to enable us to
compare the urinary excretion of Nε-HEL and 8-OHdG of
such patients to that of SLE patients. The 11 patients in
the second control group included patients with vasculitis
(n = 2), Sjogren’s syndrome (n = 3), rheumatoid arthritis
(n = 4), antiphospholipid syndrome (n = 1), and systemic
sclerosis (n = 1). Patients with SLE were divided into two
groups. Forty-two patients with an SLEDAI score ≥6w e r e
considered to have active SLE [20]. Twelve patients with
scant clinical manifestations and who had normal levels
of C3/C4 and anti-dsDNA were placed in the inactive
SLE group. The glucose uptake of immune cells in the
inactive SLE group was compared to that of cells from
the active SLE group. The demographic, laboratory, and
clinical data of all three groups are listed in Table 1. This
study was approved by the Institutional Review Board and
Ethical Committee, National Taiwan University Hospital,
Taipei, Taiwan. Informed consent was obtained from each
participant. Venous blood and 24-hour urine were collected
from each participant for analysis.
2.2. Detection of 24-Hour Excretion of N-Benzoyl-Glycyl-
Nε-(Hexanonyl)Lysine (Nε-HEL) and 8-Hydroxy-2-Deoxy-
guanosine (8-OHdG). We collected all urine excreted over
a 24-hour period from 26 active SLE, 11 non-SLE, and
14 healthy volunteers in clean containers. Urinary Nε-
HEL and 8-OHdG were quantiﬁed using commercially
available kits (Japan Institute for Aging, Schizuoka, Japan).
The concentration of urine creatinine (Ucre) was con-
comitantly measured. The excretion of Nε-HEL was cal-
culated as pmol/mg Ucre, and 8-OHdG was calculated as
pg/mg Ucre.
2.3. Isolation of T Lymphocytes and Polymorphonuclear Neu-
trophils from Peripheral Blood. Heparinized venous blood
obtained from participants was mixed with one-quarter
volume of 2% dextran solution (molecular weight, 464,000
daltons; Sigma-Aldrich Company, St. Louis, MO, USA)
and incubated at 37◦C for 20min. The leukocyte-rich
supernatant was collected and diluted with the same vol-
ume of Hanks’ balanced salt solution. The cell suspension
was layered on a Ficoll-Hypaque density gradient cushion
(speciﬁcgravity1.077,PharmaciaBiotech,Uppsala,Sweden)
and centrifuged at 150g for 30min. The mononuclear
cells (MNC) were aspirated from the interface and PMN
were collected from the bottom. The RBC in the PMN
suspension were lysed by incubation in 0.83% ammonium
chloride solution chilled to 4◦C for 10min. To purify the
T lymphocyte samples, the MNC suspension was positively
selected by monoclonal antihuman CD3 antibody-coated
microbeads and AutoMACS (Miltenyi Biotec, Bergisch,
Gladback, Germany), as in our previous report [21]. PMN
and T lymphocytes were more than 95% viable and pure, as
conﬁrmed by trypan blue dye exclusion and analysis with
ﬂow cytometry after staining with FITC-conjugated anti-
CD16 (for PMN) or anti-CD3 (for T cell) antibody (Sigma-
Aldrich).
2.4. Measurement of Intracellular Basal Lactate Levels in T
and PMN. Intracellular basal lactate was measured using
the method reported by Frauwirth et al. [22]. Brieﬂy, we
used enzymatic diagnostic kits (Sigma-Aldrich) to measure
the intracellular basal lactate levels (mg/dL) in cell lysates
(2 × 106 cells/mL) of T cells and PMN from normal and
SLE patients. A detailed description of the procedures can be
found in the manufacturer’s instruction booklet.
2.5. Measurement of Intracellular ATP Levels in T and PMN.
Intracellular ATP levels (nmole/106 cells/mL) in T and PMN
lysates were determined by using ATP determination kits
(Molecular Probes, Eugene, OG, USA). Detailed procedures
are described in the manufacturer’s instruction booklet.Clinical and Developmental Immunology 3
Table 1: The demographic features and clinical data of normal, active, and inactive SLE groups.
Parameters Normal (N = 52) Active SLE (N = 42) Inactive SLE (N = 12)
Age, years (mean ± S.D.) 27.3 ±8.72 5 .7 ±10.42 5 .6 ±9.4
Gender (female:male) 47:5 50:4 11:1
Disease duration — 3–9 years 4–8 years
SLEDAI score — 6–13 0–5
Serum C3 (mg/dL) 91.1 ±8.55 0 .7 ±11.18 7 .4 ±13.5
Serum C4 (mg/dL) 19.4 ±2.48 .8 ±3.21 6 .7 ±2.9
Anti-dsDNA(IU/mL) — 259.4 ±30.7 107.7 ±13.8
Medications
Prednisolone — 17.6 ±10.7mg/D 5.3 ±6.2mg/D
Azathioprine — 50–100mg/D —
Hydroxychloroquine — 400mg/D 200–400mg/D
2.6. Measurement of Spontaneous Glucose Uptake and Glucose
Transporter Expression on T and PMN
(a) Measurement of Spontaneous Glucose Uptake of the Cells
by 3H-2-Deoxy-d-Glucose Incorporation Assay. Spontaneous
g l u c o s eu p t a k eo fTa n dP M Nw a sm e a s u r e du s i n gt h e
method described by Shikhman et al. [23]. Brieﬂy, PMN
(1×107 cells/mL)wereincubatedwith10μLofradio-labeled
3H-deoxy-d-glucose (speciﬁc activity, 15–25Ci/mL; Roche
Diagnostics,Indianapolis,IN,USA)atroomtemperaturefor
7min. The cells were washed three times with cold PBS and
then lysed with Cell Death Lysis buﬀer (Sigma-Aldrich). The
radioactivity of the cells was detected by a β-counter.
(b) Measurement of Spontaneous Expression of Glucose Trans-
porters, GLUT3, and GLUT6 on T and PMN by Flow Cytome-
try. ThefacilitativeglucosetransportersGLUT-3andGLUT-
6a r ed i ﬀerentially expressed in diﬀerent mammalian blood
cells and brain tissues [11]. The spontaneous expression
of GLUT-3 and GLUT-6 glucose transporters on T and
PMN was ascertained by ﬁrst staining with FITC-labeled
monoclonal antibody against human GLUT-3 or GLUT-
6 (Chemicon Company, Temecula, CA, USA) followed by
FACSort ﬂow cytometric analysis with 488nm excitation
(Becton-Dickenson, Franklin Lakes, NJ, USA).
2.7.MeasurementofIntracellularGSHConcentrationinTand
PMN. Soluble cellular GSH concentration was measured
using BIOXYTECH GSH-400 colorimetric assay kit (OXIS
International Inc., Portland, OR, USA). Detailed procedures
are provided in the manufacturer’s instruction booklet.
Brieﬂy, the concentration of T and PMN in test samples
was adjusted to 1 × 107 cells/mL and sonicated at 100W for
60s. Only the soluble cellular forms, GSH and glutathione
disulﬁde, were detected by the kit. The detection limit of the
assay is 0.5μM/mL.
2.8. Determination of GSH-Px Enzyme Activity. We used
BIOXYTECH GPx-340 colorimetric assay kits (OXIS Inter-
nationalInc.)tomeasuretheGSH-PxenzymaticactivityofT
andPMNcelllysates.Onemilliunit(mU)ofGSH-Pxactivity
isdeﬁnedastheactivitythatcatalyzestheoxidationof1nmol
NADPH/mL/min, using an extinction molar coeﬃcient of
6.22 ×106 M−1·mL−1 for NADPH.
2.9. Determination of GSSG-R Activity. We used BIOXY-
TECH GR-340 colorimetric assay kits (OXIS International
Inc.) to measure the GSSG-R enzyme activity of T and PMN
cell lysates. The deﬁnition of 1mU of GSSG-R enzymatic
activity is the activity that catalyzes the reduction of 1nmol
NADP+/mL/min.
2.10.DetectionofGSH-PxmRNAExpressioninTandPMNby
RT-PCR. Total cellular RNA was extracted from 1 × 107/mL
of T or PMN using an Ultraspec RNA isolation kit (Biotex
Laboratories, Houston, TX, USA). Each extracted sample
(5μg) was reversely transcribed into cDNA by placement in
30μL of reverse transcriptional buﬀer for 1h at 42◦C. The
buﬀercontained50mMTris-HCl,75mMKCl,3mMMgCl2,
0.5mg oligo-dT primer, 0.5mM dNTP, 32U RNasin, 10mM
DTT, and 40U MMLV reverse transcriptase (Promega,
Madison, WI, USA) at pH 8.3. The reverse transcription
products (5μL) were added to a PCR buﬀer containing
10mM Tris-HCl, 1.5mM MgCl2,5 0m MK C l ,0 . 1 %T r i t o n
X-100,100ngforwardprimer,100ngreverseprimer,0.2mM
dTNP, 2 U DNA polymerase (Promega), and 5% DMSO.
PCR was performed in a Hybaid OmniGene DNA thermo-
cycler (Teddington, UK) with a program of denaturing at
95◦C for 1min, annealing at 50–58◦Cf o r1m i n ,a n dp r i m e r
extension at 72◦C for 1min. The ampliﬁcation was carried
out for 25–35 cycles. The reaction was stopped after a ﬁnal
extension at 72◦C for 10min followed by incubation at 25◦C.
The forward and reverse pair primers for human GSH-Px
and glyceraldehyde-3-phosphate dehydrogenase (G3PDH,
used as an internal control) are shown below:
GSH-Px: 5 -GGG GCC TGG TGG TGC TCG GCT-3  (sense),
5 -CAA TGG TCT GGA AGC GGC GGC-3  (anti-
sense),
G3PDH: 5 -ACC ACA GTC CAT GCC ATC AC-3  (sense),
5 -TCC ACC ACC CTG TTG CTG TA-3  (antisense).
The ampliﬁed PCR products were 354bp for GSH-Px
and 452bp for G3PDH.4 Clinical and Developmental Immunology
2.11.WesternBlotAnalysisofGSH-PxIsomers. TandPMNat
aconcentrationof5×106/mLwerelysedandelectrophoresed
in 10% SDS-PAGE. The distribution of GSH-Px isomers
in cell lysates was detected by monoclonal antihuman
GSH-Px antibody (MBL International, Woburn, MA, USA)
and enhanced chemiluminescence protein detection kits
(Amersham International Plc., Chalfont, Buckinghamshire,
UK) after electrotransfer to a nitrocellulose membrane.
2.12. Determination of GGT Enzymatic Activity in T and
PMN. We followed the method outlined by Carlisle et al.
to quantify GGT activity in T and PMN [18]. Brieﬂy, 1
× 106 cells were suspended in 1mL of PBS containing
2.5mM γ-glutamyl-p-nitroanilide and 60mM glycyl-glycine
at pH 7.2. After 90min of incubation at 37◦C, the cells were
centrifuged and the absorbance of the supernatant was read
at OD410 nm. The enzyme activity was calculated from the
absorbance readings, and is expressed as μmol p-nitroaniline
released/min/106 cells.
2.13. Detection of Surface-Expressed CD53 on T and
PMN. The direct immunoﬂuorescence antibody method, as
reported by Pedersen-Lane et al., was employed to stain the
CD53surfaceexpressiononTandPMN[19].WeusedFITC-
labeled mouse monoclonal antibody against human CD53
purchase from BD Biosciences (San Jose, CA, USA) for this
assay.
2.14. Statistical Analysis. All results are presented as mean ±
S.D.Thestatisticalsigniﬁcanceofdiﬀerencesbetweengroups
was assessed by nonparametric Wilcoxon rank-sum tests
using the commercially available software package: Stata/SE
8.0 for Windows. A P value ≤0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Increased Oxidative Stress in Active SLE Patients Detected
by Surrogate Urinary Biomarkers, Nε-HEL, and 8-OHdG
Excretion. Oxidative stress can induce peroxidation of
polyunsaturated fatty acid resulting in the production of Nε-
HEL [24]. In addition, C-8 in the guanine residue of DNA
is easily cleaved by hydroxyl free radicals. The production of
8-OHdG is the hydroxidative product of guanine after free
radical hydroxylation [25]. Both Nε-HEL and 8-OHdG are
excreted in the urine, and we used these oxidative products
as biomarkers for oxidative stress. We measured the 24-
hour urinary excretion of Nε-HEL, 8-OHdG and creatinine
(Ucre) concomitantly. We found Nε-HEL secretion in active
SLE patients was signiﬁcantly higher than in non-SLE and
normal individuals (Figure 1(a)). However, the excretion of
8-OHdG did not diﬀer between the 3 groups (Figure 1(b)).
These results suggest that Nε-HEL excretion is increased
in active SLE and is consistent with the ﬁndings of other
authors [1, 4]. Whether Nε-HEL urinary excretion in the
non-SLE group is abnormal cannot be determined from our
data due to the variety of diseases and the small sample
size.
3.2. Deranged Cellular Bioenergetics with Increased Intracel-
lular Basal Lactate Levels and Decreased ATP Production in
SLE T Lymphocytes and PMN. We hypothesized that both
deranged bioenergetics and defective redox capacity may
attribute to increased oxidative stress in patients with active
SLE. Accordingly, we measured the intracellular basal lactate
levels and intracellular ATP production as indicators of
cellular bioenergetics. As demonstrated in Figure 1(c), intra-
cellularbasallactatelevelsinbothSLE-TandSLE-PMNwere
higher than in normal cells. The ATP production in both T
and PMN of SLE patients was below normal (Figure 1(d)).
This may due to mitochondrial hyperpolarization in the
preexcited immune cells of active SLE in vivo [3, 26]. Our
results suggest that defective cellular bioenergetics of the
immuneactivecellsisoneofthecausesofincreasedoxidative
stress in patients with active SLE.
3.3. Decreased Glucose Uptake and GLUT-3, and GLUT-6
Expression on T and PMN of SLE Patients. To determine
whether the abnormal cellular bioenergetics of SLE immune
active cells is related to decreased glucose uptake leading to
highrateoflactateproductionandasubsequentinductionof
proapoptotic Bcl-2 gene expression even under aerobic con-
ditions [27–29], we detected cellular glucose-uptake by 3H-
2-deoxy-d-glucose incorporation. As shown in Figure 2(a)
(T lymphocytes) and Figure 3(a) (PMN), the glucose uptake
by SLE cells was signiﬁcantly lower than normal cells regard-
less of active or inactive SLE status. These results suggest
that decreased expression of facilitative glucose transporters
GLUT-3 and GLUT-6 is congenital rather than acquired in
SLE patients. This defect may contribute to deranged cellular
bioenergetics in SLE patients.
3.4. Comparison of Redox Capacity in Plasma and Diﬀerent
Normal Blood Cell Populations. Cellular redox capacity is
reduced in active SLE and is a major factor contributing
to oxidative stress. Reduced-form glutathione is one of
the most important endogenous molecules for modulating
the redox state of all animal cells [15–17]. We measured
the plasma GSH levels and intracellular GSH levels in
diﬀerent blood cell populations including T cells, PMN,
RBC, and platelets of normal individuals (Figure 4). GSH
is most abundant in the plasma and T lymphocytes and
GSH levels of PMN > RBC > platelets (Figure 4(a)). The
reduced form GSH is generated by the activity of GSH-
Px on the oxidized form, GSSG [1]. GSH-Px enzymatic
activity was higher in T and plasma than in PMN, RBC,
and platelets, paralleling GSH levels in the normal blood
subpopulations (Figure 4(b)). Although the total expression
of GSH-Px mRNA in normal T and PMN did not diﬀer in 2
cases shown in Figure 4(c), the composition and distribution
of GSH-Px isomers in normal T and normal PMN are
quite diﬀerent, as determined by 10% SDS-PAGE analysis.
As shown in Figure 4(d), T lymphocytes expressed mainly
dimer (50kDa) and tetramer (100kDa) isomers rather than
monomer (25kDa) and trimer (75kDa) isomers of GSH-
Px. In contrast, PMN expressed mainly monomer and
trimer isomers, rather than dimer and tetramer isomers,
of GSH-Px. These results are compatible with those ofClinical and Developmental Immunology 5
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Figure 1: Comparison of 24-hour urinary excretion of N-benzoyl-glycyl-Nε-(hexanoyl)lysine (Nε-HEL) and 8-hydroxy-2-deoxyguanosine
(8-OHdG), intracellular basal lactate levels, and ATP production of T lymphocytes and PMN from normal individuals, non-SLE patients,
and patients with active SLE. (a) Urinary Nε-HEL excretion denoted by pmole/mg urine creatinine (Ucre). (b) Urinary 8-OHdG excretion
denoted by ng/mg Ucre. (c) Intracellular basal lactate levels. (d) ATP production.
Misso et al. [30], who showed that normal neutrophils
contain mainly monomer and trimer isoforms of GSH-Px.
Because the GSH-Px enzymatic activity of T lymphocytes
is much higher than that of PMN, we speculated that the
dimer and tetramer isoforms of GSH-Px may possess more
potent antioxidant activity than the monomer and trimer
isoforms.
3.5. Defective Redox Capacity (GSH Levels, GSH-Px, and
GSSG-R Activity) in Plasma, T, and PMN of SLE Patients.
TheplasmaGSHlevelsinSLEpatientswasnotdiﬀerentfrom
that of normal individuals (Figure 5(a)). However, the GSH
levels in SLE-T and SLE-PMN (Figure 5(b)), and the GSH-
Px enzymatic activity in SLE-T were signiﬁcantly lower than
their normal counterparts (Figure 5(c)). The very low GSH-
Px enzyme activity in PMN made it diﬃcult to detect any
diﬀerences between SLE and normal groups (Figure 5(c)).
Unexpectedly, the distribution of the four GSH-Px isomers
in SLE-T and SLE-PMN cells was not diﬀerent from that
of their normal counterparts (Figure 5(d)). The activity
of GSSG-R, a redox-modulating enzyme that contains
active dithiol moieties for protection and repair of protein
sulfhydrylsinoxidativestresssituations[1],wasnotdiﬀerent
between normal individuals and SLE patients (Figure 5(e)).
To determine whether immunosuppressants such as gluco-
corticoids, hydroxyl-chloroquine, and azathioprine, or SLE
disease activity per se aﬀects the decreased redox capacity
observed in SLE patients, we determined the redox capacity
of T and PMN in 4 active SLE patients before and after
eﬀective treatment. We found that intracellular GSH levels in
T and PMN of nontreated active SLE patients were defective
in a manner similar to that of immunosuppressant-treated
active SLE patients, but the low intracellular GSH levels in
active SLE patients recovered after the immunosuppressant
treatmentwereeﬀective(Figures5(f)and5(g)).Theseresults
suggest that the reduced redox capacity of active SLE-T and6 Clinical and Developmental Immunology
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Figure 2: Comparison of glucose uptake and expression of glucose transporter type 3 (GLUT-3) and type 6 (GLUT-6) on T lymphocytes in
normal and active SLE groups. (a) Glucose uptake by the cells detected by 3H-2-deoxy-d-glucose incorporation after 24-hour incubation.
(b) Expression of GLUT-3 on normal and active SLE T lymphocytes. (c) Expression of GLUT-6 on normal and active SLE T lymphocytes.
SLE-PMN originates from lupus disease activity, rather than
the eﬀects of immunosuppressants.
3.6. Comparison of GGT Activity and CD53 Expression on
T and PMN of Normal and SLE Patients. Because GGT
is crucial for enhanced antioxidant capacity through the
recapture of glutathione molecules decreased intracellular
GSH levels in SLE-T and SLE-PMN may be due to reduced
GGT activity in the cells. GTT activity was below normal
in both T and PMN from active SLE patients (Figure 6(a)).
However, CD53 expression in SLE-T was not diﬀerent
from normal T (Figure 6(b), left panel). Unexpectedly, the
CD53 expression in SLE-PMN was higher than in normal
PMN (Figure 6(b), right panel). A representative case is
shown in Figure 6(c). This may suggest that a compensatory
mechanism is activated to limit oxidative damage in SLE-
PMN [2, 4, 31] that results from the GSH-Px defect of the
cells.
4. Discussion
T lymphocytes and PMN are very eﬃcient cells for body
defense. These cells need constant energy for basic house-
keeping and speciﬁc actions against infections. Oxidative
stress is increased in patients with active SLE [1–4]. Shah
et al. [32] further demonstrated that the increased oxidative
stress in SLE is related to Th1 cytokine IFN-γ and IL-
12 and to disease activity. However, there have been no
reports detailing the molecular basis of increased oxidative
stress in active SLE. In the present study, we observed
several interesting abnormalities of cellular bioenergetics
and redox capacity in SLE-T and SLE-PMN. These include
(a) increased intracellular basal lactate levels and decreased
ATP production, (b) decreased glucose-uptake by these
cells attributable to the defective expression of the glucose
transporters, GLUT-3 and GLUT-6, (c) reduced redox
capacity, including decreased intracellular GSH levels and
enzymatic activity of GSH-Px and GGT, and (d) normal
CD53 expression in SLE-T but increased expression in
SLE-PMN. In addition, some other important contributory
factors such as mitochondrial hyperpolarization, immune-
mediated systemic tissue inﬂammation/damage, or acceler-
ated atherosclerosis-mediated tissue hypoxia, may also be
involved in the increased oxidative stress that occurs in
patients with active SLE.
Glucose is a required energy source for many cells,
particularly those in the immune system. Glucose is needed
for oxidative and nonoxidative ATP production, anaerobicClinical and Developmental Immunology 7
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Figure 3: Comparison between normal and SLE-PMN glucose uptake and expression of glucose transporter type 3 (GLUT-3) and type 6
(GLUT-6). (a) Glucose uptake of the cells was detected by 3H-2-deoxy-d-glucose incorporation after 24-hour incubation. (b) Expression of
GLUT-3 on normal and active SLE-PMN. (c) Expression of GLUT-6 on normal and active SLE-PMN.
production of various sugar-containing macromolecules,
and cell proliferation [6, 27–29]. Tan et al. [33]a n dS c h u s t e r
et al. [34] demonstrated that after activation, PMN is
critically dependent on glucose uptake and glycolysis for
supplyingthenecessaryenergytoconducteﬀectorfunctions.
The bacterial products GM-CSF and phorbol myristate
acetate enhance glucose uptake by sequential activation of
neutrophilic protein tyrosine kinase C [32], p38 MAPK,
and hypoxia-inducible factor pathways [34]. Fu et al. [13]
further demonstrated that GLUT-1 and GLUT-3 expression
provides cellular fuel for immune responses. Maciver et al.
[29] showed that if glucose uptake is limited, glycolytic ﬂux
decreases to a level that no longer sustains viability, and
the proapoptotic Bcl-2 family becomes activated, promoting
cell death. This may lead to increased glycolytic capacity
and a high rate of lactate formation from glucose even
under aerobic conditions [27]. Our ﬁnding of decreased
g l u c o s eu p t a k ei nS L Ei m m u n ec e l l sm a yb er e ﬂ e c t e d
in an increase of basal lactate levels and cell apoptosis
in the patients. On the other hand, ATP generation is
mainly derived from glucose metabolism via glycolysis or
oxidative phosphorylation [35]. The elevated basal lactate
levels observed in SLE PMN suggest an anaerobic metabolic
stateintheseactivatedcells.Inaddition,comparedtonormal
cells, SLE-T and SLE-PMN tend to have decreased ATP
production (Figure 1(d)). This decreased ATP production
reﬂects mitochondrial functions impaired by activation-
induced cell death [36, 37] and decreased redox capacity in
SLE [2, 4, 30]. Abnormal glucose bioenergetics in SLE cells
owing to defective expression of GLUT-3 and GLUT-6 on the
cell surface can lead to impaired immune functions in active
SLE.8 Clinical and Developmental Immunology
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Figure 4: Comparison of intracellular reduced-form glutathione (GSH) levels, enzyme activity, and gene expression of glutathione
peroxidase (GSH-Px) in the plasma and diﬀerent blood cell populations of normal individuals. (a) Intracellular GSH levels (μM/1 ×
107 cells/mL) in T, PMN, red blood cells, platelets, and plasma of normal individuals. (b) GSH-Px enzyme activity (mU/1 × 107 cells/mL)
in plasma and diﬀerent blood cells of normal individuals. One milliunit (mU) of GSH-Px enzyme activity is the activity that catalyzes the
oxidation of 1nmol NADPH/mL/min. (c) Expression of GSH-Px mRNA in T and PMN of two normal individuals by RT-PCR, lane 1:
G3PDH (452bp, as internal control), lane 2: GSH-Px (354bp). (d) A representative case demonstrating dose-response expression of GSH-
Px isomers in a normal T and a normal PMN by Western blot. Three doses (2μL in lanes 1 and 4; 4μL in lanes 2 and 5; 10μL in lanes 3 and
6) of cell lysates (protein concentration 26mg/mL) were analyzed in Western blot probed by antihuman GSH-Px antibody. Four GSH-Px
isomers are identiﬁed as monomer (25kDa), dimer (50kDa), trimer (75kDa), and tetramer (100kDa). Two normal samples exhibited a
similar tendency.
Proinﬂammatory cytokines induce a variety of metabolic
changes in the utilization of carbohydrates and fat [38]. IL-
1β,T N F - α,a n dL P Se ﬀectively facilitate glucose uptake and
modulate the expression of diﬀerent glucose transporters in
experimental cells [38–40]. SLE serum is thought to contain
high levels of diﬀerent Proinﬂammatory cytokines including
TNF-α, IL-6, IL-12, IFN-α,a n dI F N - γ that may change
glucose transporter expression and glucose metabolism [40–
43]. We speculated that alterations in the intracellular
bioenergetics of SLE immune cells are the result of long-
term cell activation, which leads to production of a number
of Proinﬂammatory cytokines. In clinical settings, abnormal
redox states in the body ﬂuid and blood cells of patients with
some diseases, such as rheumatoid arthritis [44, 45], cardio-
vasculardisorders[46,47],andatopicasthma[48]ha v ebeen
reported. In the present study, we demonstrated that SLE-
T and SLE-PMN have impaired intracellular redox capacity
andincreasedoxidativedamage.Thedefectiveredoxcapacity
is due to SLE disease activity per se rather than the eﬀects
of immunosuppressive therapy. However, it is worth noting
that any diﬀerences between the GSH levels of T and PMN in
SLE patients and healthy individuals may be relevant to cell
functions, but is unlikely to be relevant to the total ROS load.
This is because any such diﬀerences would be masked by the
large antioxidant capacity of plasma due to GSH, catalase,
SOD, and numerous other free oxygen radical scavengers.Clinical and Developmental Immunology 9
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Figure 5:ComparisonofplasmaandintracellularGSHlevels,glutathioneperoxidase(GSH-Px)enzymeactivity,GSH-Pxisomerexpression,
and glutathione reductase (GSSG-R) enzyme activity in T and PMN from normal and active SLE groups. (a) Plasma GSH levels. (b)
Intracellular GSH levels (μM/1 × 107 cells/mL) in T and PMN of normal and SLE patients. (c) GSH-Px (mU/1 × 107 cells/mL) enzyme
activity in T and PMN of normal and active SLE group. One milliunit (mU) of GSH-Px enzyme activity is the activity that catalyzes the
reduction of 1nmol NADP+/mL/min. (d) Western blot analysis of GSH-Px isomer distribution in two cases of T and PMN from 2 normal
and 2 SLE patients. Both normal PMN and SLE-PMN contain mainly monomer (25kDa) and trimer (75kDa) isomers rather than dimer
(50kDa) and tetramer (100kDa) isomers. In contrast, dimer (50kDa) and tetramer (100kDa) isomers were the main isomers found in
normal and SLE-T cells. Lanes 1 and 2 are diﬀerent cases of PMN. Lanes 3 and 4 are diﬀerent cases of T. (e) Comparison of GSSG-R enzyme
activity in T and PMN of normal and SLE group members. (f) Intracellular GSH levels in active SLE-T before and after eﬀective treatment.
(g) Intracellular GSH levels in active SLE-PMN before and after eﬀective treatment.
The manipulation of cell redox states may become an
alternative strategy for improving immune responses in
some forms of cancer [17] and immune hyporesponsiveness
states. Furthermore, Maurice et al. [44] demonstrated that
an altered redox state is responsible for the hyporespon-
siveness of rheumatoid synovial T cells. Supplementation
of GSH with the glutathione precursor, N-acetyl-l-cysteine,
enhances mitogen-induced proliferative responses and IL-
2 production of synovial T lymphocytes. However, patients
with atopic asthma [48], ischemic heart disease [46], and
stroke [47] exhibit reduced redox capacity, but do not show
distinct immune hyporesponsiveness to external stimuli.
Wahl et al. [49] noted that chronically activated T cells such
as SLE-T rely primarily on oxidative metabolism for ATP
synthesis, suggesting that chronic antigen stimulation may
be the basis for the metabolic abnormalities seen in SLE
patients. Whether immune hyporesponsiveness in active SLE
can be restored by supplementation with glutathione or its
precursorsisnowunderinvestigation.Itwouldbeinteresting
to directly measure the ROS generation in T and PMN and
correlate it with autophagic activity, apoptosis, and other
cellular functions in active SLE patients.
In conclusion, we found that impaired glucose bioener-
getics and redox capacity in SLE-T and PMN are related to
impaired cellular immune function and increased oxidative
stress in active SLE.10 Clinical and Developmental Immunology
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Figure 6: Comparison of γ-glutamyl-transpeptidase (GGT) enzyme activity and CD53 expression in T and PMN of normal and SLE
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